Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.
about
Lipid-lowering efficacy of atorvastatinLipid lowering efficacy of atorvastatinEndoplasmic reticulum stress: a novel mechanism and therapeutic target for cardiovascular diseasesPeroxiredoxin1 prevents excessive endothelial activation and early atherosclerosis.Complexity of vitamin E metabolismInfluenza morbidity and mortality in elderly patients receiving statins: a cohort study.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.Statins and myocardial remodelling: cell and molecular pathways.Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.Evaluating oxidative stress in human cardiovascular disease: methodological aspects and considerations.No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: A meta-analysis of randomized controlled trials.Original inhibition method of excessive synthesis of pro-inflammatory cytokine of tumour necrosis factor α.Novel therapies targeting vascular endothelium.Endothelial function, arterial stiffness and lipid lowering drugs.Role of TNF-alpha in vascular dysfunction.Effects of Phyllanthus emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomized, double-blind, controlled study.Associations of high HDL cholesterol level with all-cause mortality in patients with heart failure complicating coronary heart diseaseSpectrum of pleiotropic effects of statins in heart failure.Cocoa flavanols reduce N-terminal pro-B-type natriuretic peptide in patients with chronic heart failure.Statin and Atrial Fibrilation: When does it work?Novel therapeutic strategies targeting vascular endothelium in essential hypertension.Oxidative stress and endothelial dysfunction: therapeutic implications.Conflicting effects of nitric oxide and oxidative stress in chronic heart failure: potential therapeutic strategies.Medication management of chronic heart failure in older adults.Statin therapy in heart failure: for good, for bad, or indifferent?Left ventricular ejection fraction as therapeutic target: is it the ideal marker?Inhibitory effect of statins on inflammatory cytokine production from human bronchial epithelial cells.Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials.Low-density lipoprotein levels in patients with acute heart failure.Statins and the risk of pneumonia: a population-based, nested case-control study.Effects of statin treatment on cardiac function in patients with chronic heart failure: a meta-analysis of randomized controlled trials.Evaluation of the possible nephroprotective effects of vitamin E and rosuvastatin in amikacin-induced renal injury in rats.Ivabradine on aortic stiffness in patients with heart failure.Waon therapy attenuates cardiac hypertrophy and promotes myocardial capillary growth in hypertensive rats: a comparative study with fluvastatin.
P2860
Q24187301-D6B736AC-1AC5-4979-9250-3C5D3CF1AE74Q24202363-3512DF55-DBA6-4A2B-B674-749634D3AB70Q26770193-169C0BBF-64E9-4F69-B22C-53113026D28EQ27339740-E0CD16F4-1CFF-4E87-B187-7015149D8F8BQ28068513-1C5A909A-5212-4729-87F3-4198D276863CQ30383137-EEFCD7BD-ADE5-419B-91FA-B124FF50568CQ33776230-E7A8E178-4C6E-486F-8809-3C6B6289132DQ34169725-35BCDE9A-8D7F-4A80-BB7B-C7506144BF15Q34196628-44736DDE-153A-479D-A4EF-BDB4882170BCQ35581462-5B05CB43-C351-4161-877C-B7B63E67B815Q36141348-60D6813A-ACE2-4802-8590-6941ED00C1BBQ36271575-2DC53D3F-44C5-4D33-8D8E-CA944BD20BCAQ36305630-B94202F0-4AB5-4DDD-AED5-33BCF0BEC4F7Q36684472-B11367B7-B63C-44E4-80B5-7E820399F38FQ36936335-AF6514CD-DFDC-40BA-8049-CA65D0FADA35Q37050343-2FD9CC52-217C-4372-BD77-44B2EFAEB8E7Q37074916-7B23927E-3B6B-4CDE-801F-711A0D6523FAQ37116745-5859E48A-090D-45D2-ADEA-B8C13A4C3C94Q37146694-01076EBF-A834-4DEB-9F8D-C67E2DACC105Q37177118-735A50A5-1E16-4DAA-A45F-61D35D283A05Q37495979-094A49D0-D70F-42EE-AD18-2EB783B026F0Q37798006-084C892F-C6B0-4F25-A259-B78750755ACCQ37834017-A0CCAF3F-1AA1-4176-A550-3544113D7083Q37835753-14D56A08-FE4A-49C8-93BB-9AD3F3D6A5D2Q38126374-E0BE96FD-3EAD-45BD-904E-85DA0E2B1C40Q38166321-E9199A86-54B7-44CD-9CF1-92D0E1B94F1BQ39364624-10CC5C43-9B8B-4639-A5BB-1699341B64EEQ39370185-6C14B040-BDB3-4B2E-B9D8-64D382559A06Q41874178-47A191DF-5E33-4B4E-B4C7-95213766573AQ44341877-1205F011-F78B-4C61-ACE7-D8CB23CBA885Q44356684-C73781FC-F842-496A-A171-356DE76A4946Q44845976-983C52BF-6A26-4113-8F27-3D1070C0C88BQ46830125-DFC2E372-7764-4B57-928F-06FE9498166DQ53600304-8C3BE56D-30A8-4A99-AD9F-CAC8A086C4EAQ53648300-EE97657A-A2E6-4A8F-891D-2989CBB6F133
P2860
Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Effects of combined administra ...... n patients with heart failure.
@en
Effects of combined administra ...... n patients with heart failure.
@nl
type
label
Effects of combined administra ...... n patients with heart failure.
@en
Effects of combined administra ...... n patients with heart failure.
@nl
prefLabel
Effects of combined administra ...... n patients with heart failure.
@en
Effects of combined administra ...... n patients with heart failure.
@nl
P2093
P2860
P1476
Effects of combined administra ...... n patients with heart failure.
@en
P2093
Athanasios Trikas
Carmen Vassiliadou
Charalambos Antoniades
Christos Pitsavos
Costas Tentolouris
Dimitris Tousoulis
Marina Toutouza
P2860
P304
P356
10.1016/J.EJHEART.2005.03.007
P577
2005-07-27T00:00:00Z